Skip to content
PubMed This is a summary of 91 peer-reviewed journal articles Updated
Endocrinology

Drug-Induced Osteoporosis: A Patient Guide

At a Glance

Drug-induced osteoporosis is medication-related bone weakening that may develop silently, especially with long-term steroids or hormone-suppressing cancer treatments. Early monitoring, lifestyle support, and bone-protective treatments help reduce fracture risk without stopping a vital medication.

How to Use This Guide: Medication-associated fracture risk is highly individualized based on your age, medication dose, kidney function, and overall health. The information below is meant to help you prepare for discussions with your care team. You should never stop a vital medication without medical supervision.

Drug-induced osteoporosis occurs when medications used to treat serious or chronic conditions have the unintended side effect of weakening the skeleton. Unlike the gradual bone loss associated with aging, medication-induced bone loss can happen rapidly, often disrupting the body’s delicate balance of building and breaking down bone tissue. It is important to know that this risk exists on a spectrum. This condition is most strongly associated with long-term use of systemic glucocorticoids (steroids) and hormone-suppressing therapies used in cancer care, but it can also be linked through observational evidence to more common medications like proton pump inhibitors for acid reflux or certain antidepressants [1][2].

Because bone loss itself does not cause pain, this condition is often “silent” until a fracture occurs. In many cases, medications can damage the internal architecture and quality of the bone even before a standard bone density scan shows a significant decline. This means that a fracture can happen during everyday activities, such as bending or lifting, which would not normally cause an injury. Recognizing this risk early is essential, as the most significant window for protecting bone strength often occurs within the first few months of starting a high-risk medication [3][4].

Managing drug-induced osteoporosis is a collaborative effort focused on proactive monitoring and early intervention. While you should never stop a vital medication without medical supervision, there are many strategies available to protect your skeleton while you receive the treatment you need. From specialized imaging that looks beyond simple density to modern bone-building and bone-maintaining therapies, the goal of care is to prevent fractures and ensure you can maintain your mobility and independence throughout your treatment journey [5][6].

(Note: In this guide, medical claims are backed by scientific research. References are indicated by bracketed codes, such as [1], which correspond to specific clinical studies and guidelines.)

Common questions in this guide

Which medicines are most likely to weaken my bones?
The strongest associations are with long-term systemic glucocorticoids, such as steroid medicines, and hormone-suppressing treatments used in cancer care. Proton pump inhibitors for acid reflux and some antidepressants have also been linked to bone or fracture risk, although the evidence is less direct. Your risk depends on the medicine, dose, duration, age, kidney function, and overall health.
Can drug-induced osteoporosis be present without pain?
Yes. Bone loss often causes no symptoms and may not be noticed until a fracture occurs. A fracture can happen during ordinary activities such as bending or lifting, and a change in height or posture can be a warning sign that should be discussed with a clinician.
When should I have a bone density scan if I take a high-risk medicine?
Ask your care team whether you need a baseline bone density scan and a spinal assessment before or soon after starting a high-risk medicine. The timing depends on your medication and individual risk. A normal scan does not always rule out early changes in bone quality, so your clinician may consider other assessments.
Do I need to stop a medicine that is harming my bones?
Do not stop a vital or prescribed medicine on your own. Clinicians can often address fracture risk through monitoring, lifestyle and nutritional support, and bone-protective or bone-building treatment while the primary condition continues to be treated. Ask how any bone treatment will fit with your current care.
How can I protect my bones while taking a medication that raises fracture risk?
Work with your care team on an individualized plan that may include baseline and follow-up monitoring, spinal assessment, nutrition, lifestyle adjustments, and bone-protective therapy. The goal is to reduce fractures and preserve mobility and independence without compromising treatment for your primary condition.

Get notified when new evidence is published on drug-induced osteoporosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (6)
  1. 1

    Understanding and Managing Corticosteroid-Induced Osteoporosis.

    Kobza AO, Herman D, Papaioannou A, et al.

    Open access rheumatology : research and reviews 2021; (13()):177-190 doi:10.2147/OARRR.S282606.

    PMID: 34239333
  2. 2

    Increased Risk of Fractures and Use of Proton Pump Inhibitors in Menopausal Women: A Systematic Review and Meta-Analysis.

    da Maia TF, de Camargo BG, Pereira ME, et al.

    International journal of environmental research and public health 2022; (19(20)) doi:10.3390/ijerph192013501.

    PMID: 36294082
  3. 3

    Glucocorticoid-induced osteoporosis: an update.

    Compston J

    Endocrine 2018; (61(1)):7-16 doi:10.1007/s12020-018-1588-2.

    PMID: 29691807
  4. 4

    Treatment options for glucocorticoid-induced osteoporosis.

    Chiodini I, Merlotti D, Falchetti A, Gennari L

    Expert opinion on pharmacotherapy 2020; (21(6)):721-732 doi:10.1080/14656566.2020.1721467.

    PMID: 32004105
  5. 5

    2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.

    Humphrey MB, Russell L, Danila MI, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2023; (75(12)):2088-2102 doi:10.1002/art.42646.

    PMID: 37845798
  6. 6

    Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer.

    Waqas K, Lima Ferreira J, Tsourdi E, et al.

    Journal of bone oncology 2021; (28()):100355 doi:10.1016/j.jbo.2021.100355.

    PMID: 33948427

This guide about medication-related bone loss is for informational purposes only and does not constitute medical advice. Never stop a vital medication or start a bone-protective treatment without medical supervision.